CREB-binding protein

Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024

Retrieved on: 
Tuesday, January 16, 2024
MSD, PRISM, Renal cell carcinoma, Hypoxia, Patient, HCC, Research, Neoplasm, Meta-analysis, Oxidative stress, Rescue coordination centre, RCC, Merck & Co., ASCO, Cell lineage, Everolimus, Society, Pembrolizumab, Headquarters, FGFR2, Deep, Cholangiocarcinoma, Drug discovery, Hepatocellular carcinoma, Cancer, Food, Proteostasis, CBP, Safety, Abstract, Food and Drug Administration, FDA, Inflammation, CREB-binding protein, Biomarker, LEAP, TKI, Merck, Differentiable function, Pharmaceutical industry

TOKYO, Jan 16, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of oncology research at two upcoming medical meetings taking place in-person in San Francisco, California and virtually.

Key Points: 
  • TOKYO, Jan 16, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of oncology research at two upcoming medical meetings taking place in-person in San Francisco, California and virtually.
  • First, the company will share findings in hepatocellular carcinoma (HCC) and cholangiocarcinoma during the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI24), which is taking place from January 18-20.
  • Tasurgratinib, for which a marketing authorization application was submitted in Japan in December 2023, is an orally available selective tyrosine kinase inhibitor of FGFR1-3.
  • Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these domains, with the aim of contributing to the cure of cancers.

Eisai Furthers Oncology Research in Gastrointestinal Cancer Treatment with New Data at ASCO GI 2024

Retrieved on: 
Tuesday, January 16, 2024
Senior, Patient, HCC, Research, Neoplasm, ASCO, Society, Liver cancer, FGFR2, Hepatocellular carcinoma, Apoptosis, CBP, Safety, Abstract, FDA, Gastrointestinal cancer, CREB-binding protein, Biomarker, Merck, LEAP, TKI, Pharmaceutical industry

NUTLEY, N.J., Jan. 16, 2024 /PRNewswire/ -- Eisai announced today the presentation of gastrointestinal cancer research during the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI24), which is taking place in-person in San Francisco, California and virtually from January 18-20.

Key Points: 
  • "We look forward to convening in San Francisco to share longer-term efficacy and safety results from the Phase 3 LEAP-002 trial with the scientific community at ASCO GI 2024.
  • Tasurgratinib, for which a marketing authorization application was submitted in Japan in December 2023, is an orally available selective TKI of FGFR1-3.
  • There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
  • These abstracts will be made available via the ASCO website on Tuesday, January 16, 2024, at 5:00 PM EST (2:00 PM PST).

Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023

Retrieved on: 
Wednesday, May 24, 2023
MSD, CREB-binding protein, Apoptosis, Carcinoma, Abstract, Senior, CBP, FR, Pembrolizumab, Cancer, Fallopian tube cancer, Bristol Myers Squibb, Research, Lung cancer, Trial of the century, ASCO, LEAP, Endometrial cancer, American Society of Clinical Oncology, Patient, Physician, Sorafenib, Oncology nursing, Annual general meeting, ADC, Merck, Poster, Merck & Co., FDA, Survival analysis, Ovarian cancer, Society, HCC, Safety, Nivolumab, Pharmaceutical industry, Eisai

Eisai entered into a joint development agreement with BlissBio for BB-1701 with option rights for a strategic collaboration in April 2023.

Key Points: 
  • Eisai entered into a joint development agreement with BlissBio for BB-1701 with option rights for a strategic collaboration in April 2023.
  • A Phase 1/2 clinical study of BB-1701 in the U.S. and China for HER2-expressing solid tumors is currently underway.
  • There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
  • Eisai and Merck are studying the LENVIMA plus KEYTRUDA combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program in various tumor types across more than multiple clinical trials.

Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023

Retrieved on: 
Tuesday, May 23, 2023
CREB-binding protein, Carcinoma, Abstract, Senior, CBP, Cancer, Research, Trial of the century, ASCO, American Society of Clinical Oncology, Patient, Physician, Sorafenib, Oncology nursing, Annual general meeting, ADC, Poster, FDA, Survival analysis, Society, HCC, Safety, Nivolumab, Pharmaceutical industry, Eisai

NUTLEY, N.J., May 23, 2023 /PRNewswire/ -- Eisai announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO23), which is taking place virtually and in-person in Chicago, Illinois from June 2 to 6.

Key Points: 
  • Eisai entered into a joint development agreement with BlissBio for BB-1701 with option rights for a strategic collaboration in April 2023.
  • A Phase 1/2 clinical study of BB-1701 in the U.S. and China for HER2-expressing solid tumors is currently underway.
  • There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
  • These abstracts will be made available on Thursday, May 25, 2023 at 5:00 PM EDT.

Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023

Retrieved on: 
Wednesday, January 18, 2023
MSD, Headquarters, TRADD, PRISM, Nivolumab, ASCO, Esophageal cancer, Stomach, Colorectal cancer, Pharmacokinetics, Safety, FDA, CBP, American Society of Clinical Oncology, Senior, Research, Gastrointestinal cancer, CREB-binding protein, Eisai, Patient, Merck Sharp & Dohme Federal Credit Union, Merck & Co., Society, LEAP, Medical imaging, Pharmaceutical industry, Merck

Based on these additional analyses, further investigation of safety, preliminary efficacy, pharmacokinetics and biomarker analyses of E7386 is ongoing using two dose levels in the expansion part.

Key Points: 
  • Based on these additional analyses, further investigation of safety, preliminary efficacy, pharmacokinetics and biomarker analyses of E7386 is ongoing using two dose levels in the expansion part.
  • Additional presentations on Eisai's oncology pipeline showcase Eisai's investigational compound, E7389- LF, a new liposomal formulation of eribulin, in combination with nivolumab in patients with solid tumors.
  • Efficacy and safety were evaluated in expansion cohorts, including an esophageal cancer cohort (NCT04078295; Abstract: #337) and a gastric cancer cohort (NCT04078295; Abstract: #339).
  • To date, more than 10 trials have been initiated under the LEAP clinical program, which is evaluating the combination across multiple tumor types.

The CREB-binding protein (CBP)/beta-catenin inhibitor E7386, co-created by Eisai and PRISM BioLab, achieved the clinical POC (Proof of Concept)

Retrieved on: 
Monday, November 1, 2021
Dai, Fibrosis, CREB-binding protein, Neurology, Sustainable Development Goal 3, Cancer, Research, Organogenesis, Cell proliferation, RAS, MYC, Atomic mass, Merck, PRISM, Sustainable Development Goals, CBP, Patient, Drug discovery, Achievement, Oncology, Differentiable function, POC, Hepatocellular carcinoma, APC, Merck & Co., Wnt signaling pathway, Senior, Gastrulation, CEO, Biomarker, Mammal, Drosophila, Morphogenesis, Adenomatous polyposis coli, Pembrolizumab, PCP, Gene expression, Pharmaceutical industry

The E7386 targets, beta-catenin, is considered to be one of the undruggable targets that are particularly difficult to develop into drug discovery.

Key Points: 
  • The E7386 targets, beta-catenin, is considered to be one of the undruggable targets that are particularly difficult to develop into drug discovery.
  • E7386 is a CBP / beta-catenin inhibitor that inhibits CBP and beta-catenin protein-protein interactions and regulates the Wnt signal-dependent gene expression.
  • (1)
    Based on the POC achievement, Eisai has initiated a phase Ib/II clinical trial (Study 201) of E7386 in combination with anti-PD-1 therapy pembrolizumab for solid tumors in Japan.
  • E7386 is a CBP / beta-catenin inhibitor that inhibits protein-protein interactions between the transcription coactivator CBP and beta-catenin, and regulates the Wnt signaling-dependent gene expression.